Scancell Holdings (GB:SCLP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Scancell Holdings has announced that Genmab has exercised its option for a second commercial license agreement, granting Genmab exclusive rights to develop and commercialize a monoclonal antibody from Scancell’s GlyMab® platform. This move could potentially yield Scancell up to $630 million in milestone payments and royalties from net sales. This strategic partnership highlights Scancell’s innovative approach in developing therapeutics targeting cancer-specific glycans.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
